首页> 外文期刊>British Journal of Clinical Pharmacology >Skin manifestations of drug allergy
【24h】

Skin manifestations of drug allergy

机译:药物过敏的皮肤表现

获取原文
获取原文并翻译 | 示例
           

摘要

Cutaneous adverse drug reactions range from mild to severe and from those localized only to skin to those associated with systemic disease. It is important to distinguish features of cutaneous drug reactions which help classify the underlying mechanism and likely prognosis as both of these influence management decisions, some of which necessarily have to be taken rapidly. Severe cutaneous reactions are generally T cell-mediated, yet this immunological process is frequently poorly understood and principles for identification of the culprit drug are different to those of IgE mediated allergic reactions. Furthermore, intervention in severe skin manifestations of drug allergy is frequently necessary. However, a substantial literature reports on success or otherwise of glucocorticoids, cyclophsphamide, ciclosporin, intravenous immunoglobulin and anti-tumour necrosis factor therapy for the treatment of toxic epidermal necrolysis without clear consensus. As well as reviewing the recommended supportive measures and evidence base for interventions, this review aims to provide a mechanistic overview relating to a proposed clinical classification to assist the assessment and management of these complex patients.
机译:皮肤药物不良反应的范围从轻度到严重,从仅局限于皮肤的反应到与全身性疾病相关的反应。重要的是要区分皮肤药物反应的特征,这些特征有助于对潜在的机制和可能的预后进行分类,因为这两种因素都会影响管理决策,其中某些决策必须迅速采取。严重的皮肤反应通常是T细胞介导的,但对这种免疫学过程的了解却很少,并且鉴定罪魁祸首药物的原理与IgE介导的过敏反应不同。此外,经常需要对药物过敏的严重皮肤表现进行干预。然而,大量文献报道了糖皮质激素,环磷酰胺,环孢菌素,静脉内免疫球蛋白和抗肿瘤坏死因子疗法是否成功用于治疗毒性表皮坏死,尚无明确共识。除了审查建议的支持措施和干预措施的证据基础外,本次审查旨在提供与拟议的临床分类有关的机制概述,以帮助评估和管理这些复杂的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号